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The progression of normal cells to a tumorigenic and metastatic state involves the accumulation of mutations in multiple key
signaling proteins, encoded by oncogenes and tumor suppressor genes. Recently, members of the TRP channel family have been
included in the oncogenic and tumor suppressor protein family. TRPM1, TRPM8, and TRPV6 are considered to be tumor
suppressors and oncogenes in localized melanoma and prostate cancer, respectively. Herein, we focus our attention on the
antioncogenic properties of TRPV1. Changes in TRPV1 expression occur during the development of transitional cell carcinoma
(TCC) of human bladder. A progressive decrease in TRPV1 expression as the TCC stage increases triggers the development of a
more aggressive gene phenotype and invasiveness. Finally, downregulation of TRPV1 represents a negative prognostic factor in
TCC patients. The knowledge of the mechanism controlling TRPV1 expression might improve the diagnosis and new therapeutic
strategies in bladder cancer.
1. Part1
1.1. TRPV1: Structure and Function. The TRPV1 channel is
predicted to have six transmembrane domains and a short,
pore-forming hydrophobic stretch between the ﬁfth and
sixth transmembrane domains. It is activated by capsaicin
[1], noxious heat (>43◦C), low pH (5.2) [1–3], voltage [4, 5],
various lipids [2, 6–11], and other pungent compounds
such as zingerone, piperine, and those found in garlic
and onion, such as allicin [12]. Similar to other six-
transmembrane domain channels, TRPV1 probably forms
a tetrameric quaternary structure [13], where each subunit
contributes to the ion-conducting pore and the selectivity
ﬁlter. Although all known TRP channels are cation selective,
their permeability for diﬀerent monovalent and divalent
cationsvariesamongtheirsubtypes[14–16].Ionpermeation
is controlled by allosteric interactions among the subunits
and by an activation gate which, as for voltage-gated potas-
sium channels, is most probably located in the innermost
region of the S6 segment [17, 18]. In this regard TRPV1
channels also exhibit voltage-dependent behaviour [19].
Splice variants of the TRPV1 channel have been reported
in several species. For example, the human TRPV1b splice
variant, which lacks exon 7 corresponding to 60 aminoacids
in the N-terminal region of the channel, can be found
in DRG neurons and in the CNS [20]. It was ﬁrst
reported that TRPV1b could be activated by heat, but
not by capsaicin or low pH [21]. However, in a more
recent study it was demonstrated that this splice variant is
unresponsive to vanilloid agonists, heat, and protons and
can inhibit channel function by associating with canon-
ical TRPV1, functioning as a dominant-negative variant,
thus suggesting that it constitutes an endogenous TRPV1
modulator.2 ISRN Urology
1.2. Expression of TRPV1 Channel in Normal Bladder Urothe-
lium. Initially, TRPV1 expression was thought to be re-
stricted to small diameter neurons within sensory ganglia
[22]. Then, several studies have demonstrated the presence
of TRPV1 also in nonneuronal cells and tissues such as rat
thymocytes [23], human epidermal keratinocytes [24–26],
smooth muscle [27], mast cells [25, 28], and hepatic stellate
cells [29].
In the urinary bladder, the capsaicin-gated ion channel
TRPV1 has been found to be expressed within aﬀerent nerve
terminals in rodent and in human species [30–32]. TRPV1-
immunoreactive ﬁbres were found in the mucosa and
muscular layer of the entire urinary tract, among epithelial
cells or closely apposed to smooth muscle cells. The ﬁrst
description of the expression of TRPV1 in rat urothelium,
both at mRNA and protein levels, was by Birder group [30],
that showed the expression of TRPV1 in basal and apical
UCs lining the bladder lumen and in the interstitial cells.
However, at present these data are in part questionable,
since other studies have provided diﬀerent evidence on
the expression of TRPV1 in mouse, rat, and guinea pig
UCs. Thus, Yamada et al. demonstrated barely detectable
PCR product for TRPV1 in isolated mouse urothelium
[33] ;E v e r a e r t se ta l .[ 34, 35] found negligible expression
of TRPV1 mRNA, and they were unable to detect TRPV1
protein expression in mouse and rat UCs by using diﬀerent
specie-speciﬁc antibodies. By patch clamp electrophysiology,
Xu et al. have demonstrated absence of capsaicin-evocated
currents in urothelial cells from guinea pig [36]. Finally, Yu
and Hill have recently failed to detect TRPV1 protein in
mouse urothelium [37]. In this view, caution is necessary
in the evaluation of the expression of TRPV1 protein in
UCs from diﬀerent species. The reasons for the confusion
about urothelial expression include specie-speciﬁcity, low
expression levels in some cases, presence of alternative splice
variants of TRPV1, like TRPV1b [20, 38], poor speciﬁcity of
antibody, the presence of nonurothelial cells in the urothe-
lium, aspeciﬁc absorption of antibodies in the urothelium,
culture conditions of na¨ ıve UCs, and so forth [37].
In human, Lazzeri et al. [39, 40]h a v ee x h a u s t i v e l yd e -
monstrated the expression of TRPV1 mainly in the super-
ﬁcial urothelial cells, and recently its expression was con-
ﬁrmed by Charrua et al. [41]. Mechanical distention of
the urothelium of isolated TRPV1 knockout (TRPV1−/−)
mice bladders resulted in substantial decrease in ATP release
[42], suggesting that TRPV1 has a functional role in normal
bladder aﬀerent mechanisms, for perception of mechanical
and irritant stimuli [30, 42]. Exposure of UCs from TRPV1
knockout (TRPV1−/−) mice to resiniferatoxin (RTX) elicited
none of the TRPV1-mediated responses, such as urothelial
NO release [30].
TRPV1 appears necessary for normal bladder function,
as TRPV1−/− mice showed abnormal urodynamic responses,
including increased frequency of nonvoiding contractions in
the awake state and decreased frequency of reﬂex voiding
contraction under anesthesia. TRPV1 appears to be required
for bladder stretch detection, acting as both an initiator
for urothelial ATP release and a mediator of hypotonically
evoked ATP release.
TRPV1-expressing aﬀerents lie in close proximity to, and
sometimes traverse, the basal cell layer, and a “functional
consortium” between urothelial and suburothelial TRPV1
has been proposed.
Patients with neurogenic detrusor overactivity (NDO)
showed an increased expression of TRPV1, both in basal
UCs and immunoreactive suburothelial nerve ﬁbers [43,
44]; however, the contribution of urothelial versus neuronal
TRPV1 has been not provided so far.
2. Part 2
2.1. TRP Channels and Tumorigenesis. The processes in-
volved in the transformation of normal cells to tumorigenic
cells and tumor progression are complex and only partly
understood [45, 46]. The progression of cells from a normal,
diﬀerentiatedstatetoatumorigenic,metastatic stateinvolves
the accumulation of mutations in multiple key signaling
proteins,encodedbyoncogenesandtumorsuppressorgenes,
together with the evolution and clonal selection of more
aggressive cell phenotypes. Some of the most important
signalingpathwaysalteredintumorigenesisenhancecellpro-
liferation and inhibit apoptosis. Ca2+ homeostasis controls
these cellular processes, including proliferation, apoptosis,
gene transcription, and angiogenesis [47].
TRP channels contribute to changes in intracellular Ca2+
concentrations,eitherbyactingasCa2+ entrypathwaysinthe
plasma membrane or via changes in membrane polarization,
modulating the driving force for Ca2+ entry mediated by
alternative pathways [48]. TRP proteins display an extraor-
dinary diversity of functional properties and have profound
eﬀects on a variety of physiological and pathological condi-
tions [48–50].
Approximately thirty TRPs have been identiﬁed to date
and are classiﬁed in seven diﬀerent families: TRPC (Canon-
ical), TRPV (Vanilloid), TRPM (Melastatin), TRPML (Mu-
colipin),TRPP(Polycystin),TRPA(Ankyrintransmembrane
protein) and TRPN (NomPC-like) [51].
In the recent years, TRP channels belonging to TRPV,
TRPC, and TRPM families have been frequently associated
with cancer growth and progression. Depending on the
stage of cancer, either increased or decreased expression of
T R Pm R N Aa n dp r o t e i nl e v e l sh a v eb e e nr e p o r t e d .T h e s e
changes may have cancer-promoting eﬀects by increasing
the expression of constitutively active TRP channels in the
plasma membrane of cancer cells, thus enhancing Ca2+-
dependent proliferative response. Alternatively, decreased
expression of TRP channels may oﬀer a survival advan-
tage, such as resistance of cancer cells to apoptotic cell
death.
At present, some of the TRP channels have been included
in the tumor suppressor and oncogenic protein family.
Indeed, in the TRPM family, TRPM1 has been suggested to
be a tumor suppressor protein, and decrease in its expression
appears to be a prognostic marker for metastasis in patients
with localized malignant melanoma [52, 53]. Similarly, in
the TRPM and TRPV family, TRPM8 and TRPV6 are
considered oncogenes and their upregulated expression inISRN Urology 3
prostate cancer may constitute new diagnostic markers for
that disease [54–56].
In the next chapter we focalize our attention on the
AntioncogenicpropertiesofanothermemberofTRPVchan-
nel family, TRPV1, by reporting published and unpublished
ﬁndings supporting the protective role exerted by this
receptor in the normal urothelium and the eﬀects of its loss
during the progression of transitional cell carcinoma (TCC)
of human bladder, in the attempt to include the TRPV1
receptor into the anti-oncogene family.
2.2. Changes in TRPV1 Expression and Function during
Neoplastic Transformation and Progression of TCC of Human
Bladder. Urinary bladder cancer is the ﬁfth most common
neoplasm and the twelfth leading cause of cancer death.
More than 90% of bladder carcinomas are TCC derived
from the uroepithelium; about 6% to 8% are squamous cell
carcinomas and 2% are adenocarcinomas. Stages Ta and Tis
(in the urothelium) and stage T1 (in the lamina propria)
are the nonmuscle-invasive stages. Most Ta tumors are low
grade, and most do not progress to invade the bladder
muscle. Stage T1 tumors are much more likely to become
muscle invasive [57]. Alghout TCC of the urinary bladder is
a chemosensitive neoplasm, metastatic disease is related with
poor prognosis and short-term survival data. The emergence
of novel biological agents oﬀers the promise of improved
outcomes, and many eﬀorts are focused on the identiﬁcation
of new approaches to enhance chemotherapeutic eﬃcacy
[58, 59].
Changes in the TRPV1 expression can occur during the
development of human urothelial cell carcinoma (UCC).
Lazzeri and colleagues have demonstrated that TCCs show
a progressive decrease in TRPV1 protein expression as the
tumor stage increases [40]. In accordancewith Lazzeri’s data,
we found [60] that TRPV1 was highly expressed at mRNA
level in low-grade UCCs whereas its expression was strongly
reduced in high-grade and stage invasive TCC (Figures
1(a) and 1(b)). Consistent with quantitative Real-time PCR
data, a marked decrease or absence of TRPV1 labelling
was found in UC specimens of high grades and stages
as diﬀerentiation levels decreased (Figure 1(c)). Treatment
of low-grade RT4 UCCs with the speciﬁc TRPV1 agonist,
capsaicin at 100μM dose, induced a TRPV1-dependent
G0/G1 cell cycle arrest and apoptosis. These events were
associated with the transcription of proapoptotic genes
includingFas/CD95,Bcl-2andcaspases,andtheactivationof
the DNA damage response pathway. Moreover, stimulation
of TRPV1 by capsaicin signiﬁcantly increased Fas/CD95
protein expression and more importantly induced a TRPV1-
dependent redistribution and clustering of Fas/CD95 that
colocalized with the vanilloid receptor (Figure 2). These
events suggest that Fas/CD95 ligand-independent TRPV1-
mediated Fas/CD95 clustering results in death-inducing sig-
nalingcomplexformationandtriggeringofapoptoticsignal-
ing through both the extrinsic and intrinsic mitochondrial-
dependent pathways [60]. In accordance with the Amantini
group, previous evidence demonstrated that TRPV1 N-
terminus binds to Fas-associated factor-1, a Fas/CD95-
associated protein [61, 62], showing regulatory functions in
TRPV1-dependent capsaicin-mediated apoptosis. Moreover,
by the use of the speciﬁc ATM inhibitor KU55933, we found
that capsaicin activates the ATM kinase involved in p53
Ser15, Ser20, and Ser392 phosphorylation. ATM activation
is involved in Fas/CD95 upregulation and coclustering with
TRPV1 as well as in UCCs growth and apoptosis.
In addition, recently ﬁndings indicated that capsaicin by
triggering ROS production, mitochondrial membrane depo-
larization, also induced a TRPV1-dependent nonapoptotic
cell death in T24 bladder cancer cells [63].
Capsaicin has been found to exhibit either tumor-pro-
moting or suppressing eﬀects, in a receptor-dependent
manner [64, 65]. We have recently provided evidence
that capsaicin treatment induced a more aggressive gene
phenotype and invasiveness in 5637 UCCs lacking TRPV1
receptor.CapsaicintreatmentofUCCsinducedupregulation
of proangiogenetic (ANGPT1, ANGPT2, and VEGF), proin-
vasive and prometastatic genes (MMP1, MMP9, TIMP1,
TIMP3, GZMA, NM23A, S100A) with a downregulation
of apoptotic genes (Fas/CD95 and TNFRSF1A). Capsaicin
increased the invasiveness of UCCs by triggering IGF-I
release, granzyme A and MMP9 activation, α-tubulin disas-
sembly, and cytoskeleton degradation (Figure 3). Finally, in
5637 UCCs transfected with the TRPV1 cDNA, we found an
increase of capsaicin-mediated calcium level, growth inhibi-
tion, and apoptosis. Moreover, capsaicin-induced migration
and MMP9 activation were reverted, suggesting that TRPV1
played an inhibitory role in UCC invasion and metastasis
[65].
In regard to the involvement of TRPV1 in capsaicin-
induced antitumour eﬀect in vivo, at present few data have
been provided so far. In vivo experiments using capsaicin
(5mg/Kg body weight) injected once every 3 days during 4
weeks peritumorally in nude mice, showed that this vanilloid
induced an antiproliferative eﬀect and signiﬁcantly slowed
the growth of T24 bladder cancer xenografts [63]. Moreover,
capsaicin at the concentration inducing apoptosis of MBT-
2 murine bladder tumor cells, by reducing the level of
reactive oxygen species and lipid peroxidation, enhances
the anti-tumor eﬀect of Bacillus Calmette-Guerin (BCG)
in bladder cancer treatment [66]. Similarly, subcutaneous
injection of capsaicin (5mg/Kg body weight) in nude mice
suppressed androgen-independent PC-3 prostate cancer cell
growth in all tumors investigated and induced apoptosis
of tumor cells [67]. Contradictory results were obtained
by using subcutaneous injection of capsazepine (CPZ), a
TRPV1 antagonist (5mg/Kg body weight) in nude mice, that
suppressed androgen-independent PC-3 prostate cancer cell
growth [67]. Several reports indicate that CPZ is not the best
TRPV1 antagonist, because sometimes it shows agonistic
eﬀects similar or better than capsaicin [2]. However, the in
vivoagonisticeﬀectofCPZmaybealsoevaluatedontheview
of the ability of the TRPV1 antagonists themselves to cause
hyperthermia and consequently cell death in prostate cancer
cells [68]. At present hyperthermia and intravesical therapy
represent the gold-standard therapy in the management
of TCCs [69, 70]. Long-term outcomes of randomized
controlled trial have clearly demonstrated the superiority
of the chemo- (mitomycin C-) hyperthermia regimen as4 ISRN Urology
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Figure 1: TRPV1 mRNA and protein expression in urothelial cancer (UC) tissues at diﬀerent stages and grades. TRPV1 mRNA levels
from UC tissues at diﬀerent tumour stages (pTa–pT4) (a) and tumour grades (G1–G3) (b) were evaluated by quantitative real-time PCR.
Results (mean ± standard deviation) were normalized for β-actin expression and TRPV1 levels were expressed as relative fold with respect
to normal bladder (NB) tissues used as control (∗0.01 ≤ P<0.05; ∗∗P<0.01, Kruskal-Wallis test). Sections from paraﬃn-embedded NB
and UC tissues at diﬀerent pathological stages (pTa–pT4) were immunostained with an anti-human TRPV1 antibody (c). (A) Omission of
the primary antibody. (B) NB specimen. (C–G) UC specimens staged as pTa-pT4. Size bars: 25μm.L, lumen.
Fas/CD95
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TRPV1
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Merge
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Figure 2: Capsaicin induces clustering and colocalization of Fas/CD95 and TRPV1 in RT4 UCCs. The immunocytochemical localization
of Fas/CD95 and TRPV1 in UCCs treated with capsaicin was analyzed by confocal microscopy using an anti-Fas/CD95 mAb and a goat
anti-TRPV1 Ab followed by respective secondary Abs. Merge panel indicates overlapping between Fas/CD95 and TRPV1 proteins. Bar =
10μm.ISRN Urology 5
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Figure 3: Capsaicin stimulates invasiveness of 5637 UCCs. Total and active MMP9 levels were evaluated in UCC lysates after capsaicin
treatmentbyMMP9activityassay. Statisticalanalysis was performedbycomparingcapsaicin withuntreatedcells, normalizedfor therelative
vehicle, ∗P ≤ 0.01 (a). MMP9 levels were evaluated in UCCs treated with capsaicin alone or in combination with diﬀerent doses of pAB.
Statistical analysis was performed by comparing capsaicin-treated UCCs with capsaicin plus pAB-treated UCCs, ∗P ≤ 0.01 (b). Cell invasion
was evaluated in UCCs treated with capsaicin in combination with pAB, by Matrigel invasion assay. Statistical analysis was performed by
comparing capsaicin plus pAB-treated UCCs with capsaicin-treated UCCs, ∗P ≤ 0.01 (c). GZMA expression was evaluated in untreated
and capasicin-treated UCCs by using a FITC-conjugated anti-human GZMA mAb and cytoﬂuorimetric analysis. Numbers in the corner
represent the mean ﬂuorescence intensity. Gray areas represent the negative control (d). GZMA release was evaluated in the supernatant of
untreated and capsaicin-treated UCCs by ELISA. Statistical analysis was performed by comparing capsaicin-treated with untreated UCCs,
normalized with the relative vehicle treatments, ∗P ≤ 0.01 (e). Microtubule disassembly was evaluated by confocal microscopy using anti-
human α-tubulin and FITC-conjugated goat Abs in vehicle or capsaicin-treated UCCs. Colchicine treatment was performed as positive
control. Bar = 10μM (f). Total protein lysates from UCCs treated with capsaicin or vehicle were separated by electrophoresis and probed
with anti-human α-tubulin followed by horseradish peroxidase-conjugated goat anti-mouse Abs (g).6 ISRN Urology
compared to intravesical chemotherapy alone in terms of
recurrence-free survival of bladder cancer patients.
Intravesical instillation of curcumin inhibits TCC cell
implantation and growth in a murine superﬁcial bladder
tumor model [71]. Thus, it is rational and desirable the use
of TRPV1 antagonists as adjuvant in combination to classic
chemotherapy for bladder cancer treatment.
Finally, human TRPV1 expression has been found to be
modulated in other tumors, and the Antioncogenic role of
TRPV1 in vivo and in vitro has been further demonstrated.
Thus, TRPV1 has been found to exhibit tumor suppres-
sive activity on skin carcinogenesis in mice because of its
ability to down-regulate EGFR expression; conversely, loss of
TRPV1 expression resulted in marked increase in papilloma
development. TRPV1 by interacting with EGFR through its
terminal cytosolic domain, facilitates Cbl-mediated EGFR
ubiquitination and subsequently its degradation via the
lysosomalpathway.Inaddition,ectopicTRPV1expressionin
HEK293cellsresultedindecreasedEGFRproteinexpression,
and higher EGFR levels were observed in the skin of TRPV1-
deﬁcient mice (TRPV1−/−) as compared to wild-type con-
trol animals [72]. Moreover, a typical TRPV1 antagonist,
AMG9810, promotes mouse skin tumor development via
a signiﬁcant increase in the expression level of EGFR and
its downstream Akt/mTOR signalling pathway. Thus the
application of this compound for classical pain relief might
increase the risk of skin cancer [73]. Accordingly, curcumin
inhibits both basal and EGF-induced growth and promotes
autophagic cell death of 253JB-V and KU7 UCCs by down-
regulating EGFR protein expression and inhibiting EGFR
signalling [74]. By contrast, the cocarcinogenic eﬀects of
capsaicin on 12-O-tetradecanoylphorbol-13-acetate- (TPA-)
promoted skin carcinogenesis in vivo is mediated through
EGFR, but not by the TRPV1 receptor [75].
Finally, TRPV1 mRNA and protein expression inversely
correlated with glioma grading, with a marked loss of
TRPV1 expression in the majority of grade IV glioblastoma
tissues. TRPV1 activation by capsaicin induced apoptosis
of U373MG glioma cells, and involved rise of Ca2+ inﬂux,
p38MAPK activation, mitochondrial permeability trans-
membrane pore opening and transmembrane potential dis-
sipation, and caspase-3 activation [76]. In addition, TRPV1
expression has been also reported in human cervical cancer
cell lines and tissues, and the endocannabinoid anandamide
(AEA) induced TRPV1-dependent tumor cell apoptosis
[77]. Finally, TRPV1 stimulation completely reverted the
cannabidiol- (CBD-) mediated inhibitory eﬀect on human
cervical cancer cell invasion by blocking CBD-induced
increase of TIMP-1 MMP inhibitor [78].
2.3. Diagnostic, Prognostic, and Therapeutic Role of TRPV1 in
TCC of Human Bladder. Changes in TRP channel expression
areassociatedwithcancerdevelopmentandmetastasis.Ithas
also been suggested that some TRP channels may serve as
prognostic or diagnostic markers [31, 79]. Among the TRP
superfamily, TRPV channels (TRPV1–6) are involved mainly
in the regulation of growth and progression of genitourinary
cancers. Thus, in prostatic adenocarcinoma, TRPV1 and
TRPV6 are overexpressed with respect to healthy prostatic
tissues, and their expression levels correlate strictly with
Gleason score, pathological stage, extraprostat extension and
tumor grades [80–82].
In this regard, we have recently assessed the role of
TRPV1 mRNA downregulation as a negative prognostic fac-
tor in patients with bladder cancer [31].
By univariate analysis, cumulative survival curves cal-
culated according to the Kaplan-Meier method for the
canonicprognosticparameterssuchastumorgradeandhigh
stage (pT4), lymph nodes and distant diagnosed metastasis,
reached signiﬁcance. Notably, the reduction of TRPV1
mRNA expression was associated with a shorter survival of
urothelial cancer patients (P = 0.008) and in a subgroup
without distant diagnosed metastasis (P = 0.045) (Figure 4).
In a multivariate Cox proportional hazards regression anal-
ysis, TRPV1 mRNA expression reached signiﬁcance as an
independent prognostic factor for survival considering all
patients and the subgroup characterized by invasive stage.
Taking into account that patients with metastasis generally
have a poor prognosis [83], on a selected group with
similar tumor grade and stage without distant diagnosed
metastasis (M0) and lymph node positivity (N0), we found
that TRPV1 could diﬀerentiate survival successfully as a
valuable and independent molecular marker (Table 1). Thus,
it is conceivable that the reduced expression of TRPV1
represent a mechanism by which TCCs evade anti-invasive
and proapoptotic signals.
These ﬁndings may be particularly important in the
stratiﬁcation of urothelial cancer patients with higher risk
of tumor progression for the choice of therapy options.
Moreover, TRPV1 may be also useful to improve appropriate
selection of postoperative follow-up protocols for individual
patients.
About 70% of TCC of human bladder are superﬁcial at
initial presentation. They are tumors conﬁned to the mucosa
(70%) or lamina propria (30%). Approximatively, 50 to 70%
of these tumors recur with 10 to 30% showing grade and
stageprogression.TCCswithpT1G3accountforalmost10%
of all TCC diagnosed, with respect to pT1G2-G1. They show
a poorer prognosis with up to 50% progressing to muscle
invasion with increased recurrence and progression rate,
and invasiveness. In this regard, the signiﬁcant reduction of
TRPV1 expression we found in pT1G3 versus pT1G2 [31]
that parallel that observed at protein level by Lazzeri et al.
[40] may be particularly important in the evaluation of
the stratiﬁcation risk of recurrence and tumour progression
of invasive versus non-invasive superﬁcial TCC. Notably,
since reduction of TRPV1 expression in TCC of human
bladder was signiﬁcantly associated with a shorter survival of
urothelial cancer patients, the analysis of TRPV1 expression
in pT1 G2–G3 TCC shows the presence of a risk group
stratiﬁcation:theﬁrstgroupofpT1G2TCCpatientsshowing
a reduction of TRPV1 expression (25% of total) and the
second group showing a marked reduction of TRPV1
expression (50% of total) [31].
In addition, it has been also found that expression of
TRPV1 in TCC of human bladder is signiﬁcantly reduced
in nonmuscle-invasive versus muscle-invasive TCCs
[31]. By analyzing 54 bladder tissue samples fromISRN Urology 7
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Figure 4: Decrease of TRPV1 mRNA expression is associated with a shorter survival of TCC patients. Kaplan-Meier survival analysis for
patients without distant metastasis (M0) subgroup shows the association between survival and TRPV1 mRNA expression based on three
categories: high, moderate, and low expression (a); survival and pathological grading divided into G1, G2, and G3 grades (b). Associated
log-rank test P values were indicated for each analysis.
Table 1: Multivariate Cox proportional hazard regression analysis of clinicopathological parameters and TRPV1 mRNA expression in
relation to survival rates.
Relative risk (95% CI)
All patients (n = 62) pTa/T1 (n = 24) pT2/T3/T4 (n = 38) G2/G3 pT2/T3 N0M0
(n = 27)
TRPV1
(low/moderate/high)
0.26 (0.10–0.64)
P = 0.004
0.61 (0.07–5.03)
P = 0.65
0.30 (0.10–0.88)
P = 0.030
0.19 (0.03–1.00)
P = 0.05
Tumor grade
(G1/G2/G3)
1.52 (0.74–3.12)
P = 0.26
2.83 (0.29–27.44)
P = 0.37
2.85 (0.81–10.12)
P = 0.011
Tumor grade (G2/G3) 5.65 (0.68–47.0)
P = 0.11
Tumor stage (T2/T3) 0.43 (0.09–1.96)
P = 0.28
nonmuscle-invasive (n = 28) and muscle-invasive (n = 26)
TCC patients, we found a signiﬁcative inverse correlation
between TRPV1 mRNA expression and muscle invasiveness,
suggesting that the negative prognostic value of reduction of
TRPV1 mRNA in TCCs could be likely related to increased
invasiveness of TCC in patients expressing lower TRPV1
level. Concordantly with these preliminary data, loss of
TRPV1 in UCs was associated with a more aggressive gene
phenotype and invasiveness in UCCs [65].
Moreover, Miao et al. have recently demonstrated in
hepatocarcinoma patients that high TRPV1 expression is
associated with increased disease-free survival [84].
In regard to treatment of TCC of human bladder,
altogether we describe a novel connection between ATM
DNA damage response and FasL-independent Fas-mediated
intrinsic and extrinsic apoptotic pathways triggered by
TRPV1 stimulation on TCCs. Many cancer cells acquire
resistance to chemotherapeutic-induced cytotoxicity dur-
ing tumor progression by decreasing their sensitivity to
FasL/Fas-induced apoptosis [60]. Loss of Fas or FasL
molecules,blockingtheactiveFasLsitebysolublesFas,seems
to be induced in parallel to tumor progression. In addition,
cell death induced by some cytotoxic drugs depend to an
intact Fas system. Downregulation of Fas/FasL molecules
as well as resistance to Fas-induced apoptosis has been
reported in TCCs [71]. We found that capsaicin induces
Fas upregulation both at transcriptional and translation
levels, and more importantly FasL-independent TRPV1-
dependent apoptosis, thereby bypassing some of the escape
mechanisms triggered by TCCs. Similarly to FasL, the death
ligand TRAIL has been found to induce apoptosis and
sensitization of tumor cells to cytostatic or cytotoxic drugs8 ISRN Urology
[85]. In this regard, TRPV1 activation sensitized cancer cells
to TNFR-mediated apoptosis [85]. Capsaicin has been found
to upregulate DR5, a death receptor of TRAIL in UCCs [65].
2.4. Conclusion and Perspectives. Progress is required, not
only in characterizing TRPV1 expression, activity, and
distribution in TCCs, but also in addressing the feasibility
of these TRP proteins as drug targets. This area of research
is particularly signiﬁcant, as the potential for the pharmaco-
logical modulation of channels is one of the key advantages
over other targets.
The knowledge of the mechanism controlling TRPV1
expression would be of importance for a better understand-
ing of UCC growth and progression. In the recent years
urologistshavedevelopedahugeexperiencewithintravesical
instillations of vanilloids in the treatment of lower urinary
tract (LUT) dysfunction. In particular, agonists of TRPV1
such as RTX, arvanil, olvanil have been considered as a new
strategy to treat functional disorders of micturition reﬂex
and pelvic-perineal pain in selected group of patients refrac-
tory to common therapies [43, 86–89]. The comprehension
of the molecular mechanisms underlying their proapoptotic
activity would be clinically relevant to extend the use of
these agents also to the therapy of superﬁcial urothelial
malignancies. Thus, sustained expression of TRPV1 protein
in low-grade superﬁcial TCC and high stage-low grade
muscle-invasive TCCs permits the utilize of speciﬁc TRPV1
agonists alone or in combination with chemotherapeutic
drugs in the treatment of these tumors.
Ontheotherhand,lossofTRPV1duringtheprogression
of tumor with the acquisition of a more invasive phenotype
stimulates studies on the mechanisms responsible to the
expression of TRPV1 in TCC of human bladder. In this
regard, the involvement of miRNA and E3-ligases in the con-
trol of TRPV1 mRNA and protein expression, respectively,
and the study on the existence of a relationship between
the expression of speciﬁc TRPV1 gene single nucleotide
polymorphisms (SNPs) and splice variants and increased
cancer risk of TCC of human bladder have been approached.
Further basic studies on the structure, in vivo expression
and function of the TRPV1 channel must to be conduced
to completely understand the role of TRPV1 as tumor
suppressor gene in cancers of epithelial origins.
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